Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2017

Schrock Alexa B, Lai Andrea, Ali Siraj M, Miller Vincent A, Raez Luis E

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crizotinib

Share to Drug Resistance, Neoplasm

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 28629543
DOI: 10.1016/j.jtho.2017.02.017

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.PMID 28629543Read ↗

Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.Semantic proximity Read ↗

Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.Semantic proximity Read ↗

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.Semantic proximity Read ↗

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 SkippingSemantic proximity Read ↗

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.Semantic proximity Read ↗

A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.Semantic proximity Read ↗

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancersSemantic proximity Read ↗

Response to savolitinib in a patient with lung adenocarcinoma harboring a novel MET exon 14 skipping mutation.Semantic proximity Read ↗

Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.Semantic proximity Read ↗

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.